IP Library › Granted Patent US 12678509
Granted Patent B2
US 12678509 · App. 17/773,749 · Granted Jul 14, 2026

Inhibitor of apoptosis (IAP) protein antagonists

Inventors: Nicholas David Peter Cosford (San Diego, CA); Dominik Heimann (Hamm, DE); Peter Teriete (San Diego, CA); Sumit Kumar Chanda (La Jolla, CA); Lars Pache (San Diego, CA); Nicole Bata (San Diego, CA)
Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
A61K47/55A61P31/18A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678509
App. No.
17/773,749
Filed
May 2, 2022
Granted
Jul 14, 2026
Kind
B2
Art Unit
1625
USPC
514/211.05
Abstract

Provided herein are compounds that modulate the activity of inhibitor of apoptosis (IAPs) proteins, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Claims (31)

1 . A compound having the structure of Formula II, or pharmaceutically acceptable salt thereof:

wherein,

each X 1 is independently O (oxygen), or S (sulfur);

each R 1 , R 3 and R 4 is independently H, halogen, or C 1 -C 6 alkyl;

each R 2 is independently —NR 5 R 6 ;

each R 5 and R 6 is independently H, C 1 -C 6 alkyl, or —C 1 -C 6 alkyl-(C 3 -C 6 cycloalkyl);

each X 3 is independently —NHC(═O)—, or —C(═O)NH—;

A 1 and A 2 are each

L is —X 5 —(CH 2 ) n1 -Q 1 -(CH 2 ) n2 —X 5 —;

each X 5 is independently O or S;

each n 1 and n 2 is independently 1-3;

Q 1 is

and

each R 2a and R 2b is independently C 1 -C 6 alkyl or C 2 -C 6 alkenyl; or

R 2a and R 2b taken together form a C 3 -C 6 cycloalkyl.

2 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each R 2a and R 2b is independently C 2 -C 6 alkenyl.

3 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each X 1 is S (sulfur).

4 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 2a and R 2b taken together form a C 3 -C 6 cycloalkyl.

5 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each R 2a and R 2b is independently C 1 -C 6 alkyl.

6 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein X 3 is —NHC(═O)—.

7 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each R 1 is independently H or C 1 -C 3 alkyl.

8 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each R 2 is independently —NH 2 or NHCH 3 .

9 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each R 3 is independently H, CH 3 , or ethyl.

10 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein each R 4 is independently H or CH 3 .

11 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein

is

12 . The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein Q 1 is

13 . A compound, or pharmaceutically acceptable salt thereof, wherein the compound is:

or pharmaceutically acceptable salt thereof.

14 . A pharmaceutical composition comprising a compound of claim 1 , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15 . A method of treating a hyperproliferative disorder in an individual in need thereof comprising administering a therapeutically effective amount of a compound of claim 1 , or pharmaceutically acceptable salt thereof, to the individual, wherein the hyperproliferative disorder is associated with an upregulation of inhibitor of apoptosis (IAP) proteins in the individual.